Histiocytic Disorders Clinical Trials

 

Collaborative Clinical Trials

LCH-CLO: Clofarabine for Langerhans Cell Histiocytosis and LCH-related disorders

Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-Related Disorders

Diseases Treated:

Langerhans cell histiocytosis and LCH-related disorders

Eligibility:

  • Prior diagnosis of Langerhans cell histiocytosis or LCH-related disorder
  • Evidence of active disease
  • Performance Score > 70% (use Lansky score for age < 16 and Karnofsky score for age ≥16)
  • Any age
  • Adequate organ functions
View Trial

LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis

International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Diseases Treated:

Langerhans cell histiocytosis

Eligibility:

  • Diagnosis of Langerhans cell histiocytosis
  • Younger than 18 years old
  • Meets inclusion criteria for the respective stratum

 

View Trial